The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 8.71 — safe zoneOK
- Earnings-manipulation signal · Beneish M -1.75 — flag raised, worth a closer lookWatch
- Earnings quality 47/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as GYRE THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Product$106.1M
- Contiva$5.5M
- Etorel$4.6M
- Other Product$312K
Leadership changes
From GYRE THERAPEUTICS, INC.'s own filings, the day they're filed.
- Dan Weng · director · appointmenteff. 2025-08-18
- Ping Zhang · director · appointmenteff. 2025-01-05
- Ying Luo · Chairman · departureeff. 2024-12-31
Latest filings
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-14
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about GYRE THERAPEUTICS, INC., every answer cited🔒
- The Intelligence Brief — added when GYRE THERAPEUTICS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.